Kairos Pharma Ltd KAPA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $0.46
- Day Range
- $0.41–0.47
- 52-Week Range
- $0.38–7.28
- Bid/Ask
- $0.37 / $0.47
- Shares Outstanding
- 4.69M
- Market Cap
- $2.04M
- Volume/Avg
- 33,757 / 355,043
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
- Website
- https://www.kairospharma.com
Valuation
Metric | KAPA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.42 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KAPA |
|---|---|
Quick Ratio | 6.31 |
Current Ratio | 6.77 |
Interest Coverage | — |
Quick Ratio
KAPA
Profitability
Metric | KAPA |
|---|---|
Return on Assets (Normalized) | −99.65% |
Return on Equity (Normalized) | −106.18% |
Return on Invested Capital (Normalized) | −108.73% |
Return on Assets
KAPA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|pW#lSxd | LOCK|lz@R | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|fL!@?S! | LOCK|R&Ddh | $95B | |||
| Moderna Inc MRNA | LOCK|h#?B@^^ | LOCK|w^ | $79B | |||
| argenx SE ADR ARGX | LOCK|jMj&K%? | LOCK|@KL | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|MpF@mwb | LOCK|D%D | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|SwxV?v! | LOCK|m&gx | $30B | |||
| Incyte Corp INCY | LOCK|#qc%rY | LOCK|FpJ | $23B | |||
| BioNTech SE ADR BNTX | LOCK|@pF?^sd | LOCK|^b | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#^%vd@? | LOCK|Zn>S | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|@HC%!@f | LOCK|##< | $15B |